Innovent Biologics, Inc. delivered solid FY2025 results that demonstrate the resilience and earnings power of its business model. Revenue of HK$13.04B and net income of HK$813.6M reflect the company's sustained competitive advantages across its core Biotechnology operations. The Healthcare sector co
Access the complete analysis, financial model, price target breakdown, and risk factors.
Read Full Report →2 free reads per day · No credit card required